Brought to you by 
Acceleron and Celgene expand relationship through new ACE536 deal
13 Nov 2019
Executive Summary
Acceleron Pharma Inc. (therapeutics for orphan diseases and cancer) and Celgene Corp. are expanding their relationship, this time agreeing to work together on Acceleron’s preclinical anemia candidate ACE536.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acceleron and Celgene expand relationship through new ACE536 deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice